PRENTISS DRUG & CHEMICAL CO., INC. – Trademark Portfolio
Entity Type: 03
PRENTISS DRUG & CHEMICAL CO., INC. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include PBO-8, MEELIUM, and PRENTOX. The owner is based in NEW YORK, NY.
101 W. 31ST. ST.
NEW YORK, NY 10001
Showing of trademarks Trademarks
Trademark Classifications
PRENTISS DRUG & CHEMICAL CO., INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PRENTISS DRUG & CHEMICAL CO., INC. have?
PRENTISS DRUG & CHEMICAL CO., INC. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 cancelled.
What trademark classes does PRENTISS DRUG & CHEMICAL CO., INC. file in?
PRENTISS DRUG & CHEMICAL CO., INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are PRENTISS DRUG & CHEMICAL CO., INC.'s most well-known trademarks?
PRENTISS DRUG & CHEMICAL CO., INC.'s registered trademark portfolio includes well-known marks such as PBO-8, MEELIUM, and PRENTOX. These are among 3 currently registered trademarks in the portfolio.
What is PRENTISS DRUG & CHEMICAL CO., INC.'s trademark registration success rate?
PRENTISS DRUG & CHEMICAL CO., INC. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.